# ClearPoint Neuro, Inc.: financial statements, quarterly

CLPT · Nasdaq · CIK 1285550 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/clpt.md) · [Financials](/companies/clpt/financials.md) · [Filings](/companies/clpt/filings.md) · [Insiders](/companies/clpt/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/clpt/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [6.8 d](/filings/0000950170-25-027934.md) | [7.6](/filings/0000950170-25-070545.md) | [7.9](/filings/0001285550-25-000012.md) | [8.1](/filings/0001193125-25-270123.md) | [7.8 d](/filings/0001193125-26-111231.md) | [8.5](/filings/0001193125-26-221890.md) | [9.2](/filings/0001193125-26-330842.md) | [8.9](/filings/0001193125-26-436412.md) | [10.4 d](/filings/0001193125-26-111231.md) | [12.1](/filings/0001193125-26-221890.md) | [10.9](/filings/0001193125-26-330842.md) | [12.1](/filings/0001193125-26-436412.md) |
| Cost of revenue | $m | [2.8 d](/filings/0000950170-25-027934.md) | [3.1](/filings/0000950170-25-070545.md) | [2.9](/filings/0001285550-25-000012.md) | [3.3](/filings/0001193125-25-270123.md) | [3.0 d](/filings/0001193125-26-111231.md) | [3.4](/filings/0001193125-26-221890.md) | [3.7](/filings/0001193125-26-330842.md) | [3.3](/filings/0001193125-26-436412.md) | [4.0 d](/filings/0001193125-26-111231.md) | [4.4](/filings/0001193125-26-221890.md) | [4.2](/filings/0001193125-26-330842.md) | [5.0](/filings/0001193125-26-436412.md) |
| Gross profit | $m | [4.0 d](/filings/0000950170-25-027934.md) | [4.5](/filings/0000950170-25-070545.md) | [5.0](/filings/0001285550-25-000012.md) | [4.8](/filings/0001193125-25-270123.md) | [4.8 d](/filings/0001193125-26-111231.md) | [5.1](/filings/0001193125-26-221890.md) | [5.6](/filings/0001193125-26-330842.md) | [5.6](/filings/0001193125-26-436412.md) | [6.4 d](/filings/0001193125-26-111231.md) | [7.8](/filings/0001193125-26-221890.md) | [6.7](/filings/0001193125-26-330842.md) | [7.1](/filings/0001193125-26-436412.md) |
| Research and development | $m | [2.7 d](/filings/0000950170-25-027934.md) | [2.6](/filings/0000950170-25-070545.md) | [3.1](/filings/0001285550-25-000012.md) | [3.3](/filings/0001193125-25-270123.md) | [3.3 d](/filings/0001193125-26-111231.md) | [3.4](/filings/0001193125-26-221890.md) | [3.8](/filings/0001193125-26-330842.md) | [3.5](/filings/0001193125-26-436412.md) | [3.2 d](/filings/0001193125-26-111231.md) | [4.5](/filings/0001193125-26-221890.md) | [4.6](/filings/0001193125-26-330842.md) | [4.0](/filings/0001193125-26-436412.md) |
| Selling, general and administrative | $m | [2.7 d](/filings/0000950170-25-027934.md) | [2.8](/filings/0000950170-25-070545.md) | [2.8](/filings/0001285550-25-000012.md) | [3.1](/filings/0001193125-25-270123.md) | [3.3 d](/filings/0001193125-26-111231.md) | [4.1](/filings/0001193125-26-221890.md) | [3.4](/filings/0001193125-26-330842.md) | [3.6](/filings/0001193125-26-436412.md) | [5.4 d](/filings/0001193125-26-111231.md) | [5.0](/filings/0001193125-26-221890.md) | [5.6](/filings/0001193125-26-330842.md) | [3.8](/filings/0001193125-26-436412.md) |
| Operating income | $m | [(4.7) d](/filings/0000950170-25-027934.md) | [(4.2)](/filings/0000950170-25-070545.md) | [(4.7)](/filings/0001285550-25-000012.md) | [(5.2)](/filings/0001193125-25-270123.md) | [(5.6) d](/filings/0001193125-26-111231.md) | [(6.2)](/filings/0001193125-26-221890.md) | [(5.7)](/filings/0001193125-26-330842.md) | [(5.3)](/filings/0001193125-26-436412.md) | [(7.0) d](/filings/0001193125-26-111231.md) | [(8.5)](/filings/0001193125-26-221890.md) | [(10.2)](/filings/0001193125-26-330842.md) | [(6.3)](/filings/0001193125-26-436412.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-221890.md) | [0.4](/filings/0001193125-26-330842.md) | [0.9](/filings/0001193125-26-436412.md) | [1.1 d](/filings/0001193125-26-111231.md) | [1.4](/filings/0001193125-26-221890.md) | [1.4](/filings/0001193125-26-330842.md) | [1.4](/filings/0001193125-26-436412.md) |
| Income tax | $m | not reported | [0.0](/filings/0000950170-25-070545.md) | [0.0](/filings/0001285550-25-000012.md) | [0.0](/filings/0001193125-25-270123.md) | [(0.0) d](/filings/0001193125-26-111231.md) | [0.0](/filings/0001193125-26-221890.md) | [0.0](/filings/0001193125-26-330842.md) | [0.0](/filings/0001193125-26-436412.md) | [0.0 d](/filings/0001193125-26-111231.md) | [0.0](/filings/0001193125-26-221890.md) | [(0.0)](/filings/0001193125-26-330842.md) | [(0.0)](/filings/0001193125-26-436412.md) |
| Net income | $m | [(4.6) d](/filings/0000950170-25-027934.md) | [(4.1)](/filings/0001193125-25-270123.md) | [(4.4)](/filings/0001193125-25-270123.md) | [(5.0)](/filings/0001193125-25-270123.md) | [(5.4) d](/filings/0001193125-26-111231.md) | [(6.0)](/filings/0001193125-26-436412.md) | [(5.8)](/filings/0001193125-26-436412.md) | [(5.9)](/filings/0001193125-26-436412.md) | [(7.8) d](/filings/0001193125-26-111231.md) | [(9.6)](/filings/0001193125-26-436412.md) | [(11.3)](/filings/0001193125-26-436412.md) | [(7.5)](/filings/0001193125-26-436412.md) |
| Diluted EPS | $ per share | not reported | [(0.16)](/filings/0000950170-25-070545.md) | [(0.16)](/filings/0001285550-25-000012.md) | [(0.18)](/filings/0001193125-25-270123.md) | not reported | [(0.22)](/filings/0001193125-26-221890.md) | [(0.21)](/filings/0001193125-26-330842.md) | [(0.21)](/filings/0001193125-26-436412.md) | not reported | [(0.32)](/filings/0001193125-26-221890.md) | [(0.38)](/filings/0001193125-26-330842.md) | [(0.24)](/filings/0001193125-26-436412.md) |
| Basic EPS | $ per share | not reported | [(0.16)](/filings/0000950170-25-070545.md) | [(0.16)](/filings/0001285550-25-000012.md) | [(0.18)](/filings/0001193125-25-270123.md) | not reported | [(0.22)](/filings/0001193125-26-221890.md) | [(0.21)](/filings/0001193125-26-330842.md) | [(0.21)](/filings/0001193125-26-436412.md) | not reported | [(0.32)](/filings/0001193125-26-221890.md) | [(0.38)](/filings/0001193125-26-330842.md) | [(0.24)](/filings/0001193125-26-436412.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [23.1](/filings/0000950170-25-027934.md) | [35.4](/filings/0001285550-24-000051.md) | [32.8](/filings/0001285550-25-000012.md) | [21.6](/filings/0001193125-25-270123.md) | [20.1](/filings/0001193125-26-111231.md) | [12.4](/filings/0001193125-26-221890.md) | [41.5](/filings/0001193125-26-330842.md) | [38.2](/filings/0001193125-26-436412.md) | [45.9](/filings/0001193125-26-436412.md) | [35.6](/filings/0001193125-26-221890.md) | [29.4](/filings/0001193125-26-330842.md) | [46.2](/filings/0001193125-26-436412.md) |
| Current assets | $m | [36.2](/filings/0000950170-25-027934.md) | [47.6](/filings/0001285550-24-000051.md) | [46.6](/filings/0001285550-24-000098.md) | [34.3](/filings/0001285550-24-000121.md) | [33.4](/filings/0001193125-26-111231.md) | [24.2](/filings/0000950170-25-070545.md) | [54.0](/filings/0001285550-25-000012.md) | [51.3](/filings/0001193125-25-270123.md) | [63.6](/filings/0001193125-26-436412.md) | [54.9](/filings/0001193125-26-221890.md) | [48.9](/filings/0001193125-26-330842.md) | [66.7](/filings/0001193125-26-436412.md) |
| Total assets | $m | [42.7](/filings/0000950170-25-027934.md) | [53.6](/filings/0001285550-24-000051.md) | [52.6](/filings/0001285550-24-000098.md) | [40.2](/filings/0001285550-24-000121.md) | [39.2](/filings/0001193125-26-111231.md) | [30.1](/filings/0000950170-25-070545.md) | [62.9](/filings/0001285550-25-000012.md) | [60.4](/filings/0001193125-25-270123.md) | [97.7](/filings/0001193125-26-436412.md) | [93.4](/filings/0001193125-26-221890.md) | [86.7](/filings/0001193125-26-330842.md) | [113](/filings/0001193125-26-436412.md) |
| Current liabilities | $m | [7.4](/filings/0000950170-25-027934.md) | [15.2](/filings/0001285550-24-000051.md) | [16.7](/filings/0001285550-24-000098.md) | [7.6](/filings/0001285550-24-000121.md) | [10.4](/filings/0001193125-26-111231.md) | [6.9](/filings/0000950170-25-070545.md) | [7.4](/filings/0001285550-25-000012.md) | [8.1](/filings/0001193125-25-270123.md) | [10.8](/filings/0001193125-26-436412.md) | [9.5](/filings/0001193125-26-221890.md) | [10.3](/filings/0001193125-26-330842.md) | [9.9](/filings/0001193125-26-436412.md) |
| Total liabilities | $m | [21.5](/filings/0000950170-25-027934.md) | [19.1](/filings/0001285550-24-000051.md) | [20.4](/filings/0001285550-24-000098.md) | [11.2](/filings/0001285550-24-000121.md) | [13.8](/filings/0001193125-26-111231.md) | [10.1](/filings/0000950170-25-070545.md) | [43.1](/filings/0001285550-25-000012.md) | [44.5](/filings/0001193125-25-270123.md) | [69.7](/filings/0001193125-26-436412.md) | [74.6](/filings/0001193125-26-221890.md) | [76.0](/filings/0001193125-26-330842.md) | [85.5](/filings/0001193125-26-436412.md) |
| Long-term debt | $m | [9.9](/filings/0001285550-24-000031.md) | [10.0](/filings/0001285550-24-000051.md) | [10.0](/filings/0001285550-24-000098.md) | not reported | not reported | not reported | [28.8](/filings/0001285550-25-000012.md) | [29.2](/filings/0001193125-25-270123.md) | [49.1](/filings/0001193125-26-111231.md) | [49.6](/filings/0001193125-26-221890.md) | [50.2](/filings/0001193125-26-330842.md) | [50.8](/filings/0001193125-26-436412.md) |
| Shareholders' equity | $m | [21.2](/filings/0001193125-26-111231.md) | [34.6](/filings/0001193125-25-270123.md) | [32.1](/filings/0001193125-25-270123.md) | [29.0](/filings/0001193125-25-270123.md) | [25.4](/filings/0001193125-26-436412.md) | [20.0](/filings/0001193125-26-436412.md) | [19.7](/filings/0001193125-26-436412.md) | [15.9](/filings/0001193125-26-436412.md) | [28.0](/filings/0001193125-26-436412.md) | [18.8](/filings/0001193125-26-436412.md) | [10.8](/filings/0001193125-26-436412.md) | [27.3](/filings/0001193125-26-436412.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(1.2) d](/filings/0000950170-25-027934.md) | [(3.8)](/filings/0000950170-25-070545.md) | [(2.7) d](/filings/0001285550-25-000012.md) | [(1.2) d](/filings/0001193125-25-270123.md) | [(1.2) d](/filings/0001193125-26-111231.md) | [(6.2)](/filings/0001193125-26-221890.md) | [(2.6) d](/filings/0001193125-26-330842.md) | [(3.1) d](/filings/0001193125-26-436412.md) | [(12.1) d](/filings/0001193125-26-436412.md) | [(8.0)](/filings/0001193125-26-221890.md) | [(7.0) d](/filings/0001193125-26-330842.md) | [(20.1)](/filings/0001193125-26-436412.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-25-027934.md) | [0.0](/filings/0000950170-25-070545.md) | [0.0 d](/filings/0001285550-25-000012.md) | [0.0 d](/filings/0001193125-25-270123.md) | [0.3 d](/filings/0001193125-26-111231.md) | [0.2](/filings/0001193125-26-221890.md) | [0.1 d](/filings/0001193125-26-330842.md) | [0.2 d](/filings/0001193125-26-436412.md) | [0.0 d](/filings/0001193125-26-111231.md) | [0.6](/filings/0001193125-26-221890.md) | [0.2 d](/filings/0001193125-26-330842.md) | [0.1 d](/filings/0001193125-26-436412.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.6](/filings/0001285550-24-000051.md) | [24.6](/filings/0001285550-24-000098.md) | [24.6](/filings/0001285550-24-000121.md) | [25.5](/filings/0000950170-25-070545.md) | [27.5](/filings/0001285550-25-000012.md) | [27.6](/filings/0001193125-25-270123.md) | [27.7](/filings/0001193125-26-221890.md) | [28.3](/filings/0001193125-26-330842.md) | [28.4](/filings/0001193125-26-436412.md) | [29.5](/filings/0001193125-26-221890.md) | [30.2](/filings/0001193125-26-330842.md) | [31.0](/filings/0001193125-26-436412.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 32,054,268 at 2026-10-21, from the cover of the [10-Q filed 2026-10-28](/filings/0001193125-26-436412.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 05:15 ET. No prices; not investment advice.